Program

Only noted sessions below are available virtually. You can use the filter option to narrow down the sessions.

Poster G: Feasibility of Cardiovascular Rehabilitation for Breast Cancer Patients with Cardiotoxicity (11:30)

May 27, 2023 from 11:05am EDT to 11:45am EDT

Poster G: Feasibility of Cardiovascular Rehabilitation for Breast Cancer Patients with Cardiotoxicity - 11:30

 

The purpose of this project is to determine the feasibility of enrolling breast cancer patients treated with anthracycline +/- trastuzumab who also have a decreased left ventricular ejection fraction in cardiac rehabilitation (CR) to reduce future cardiovascular disease (CVD). With advances in early detection and treatment, the number of cancer survivors in Canada has steadily increased since the 1990s (CCS, 2021). Unfortunately, CVD remains one of the most serious and life-threatening complication of cancer treatment (Ruddy et al., 2020). One solution for preventing future CVD among cancer survivors is attendance at a CR program (Gilchrist et al., 2019). CR offers secondary prevention of CVD by providing medical evaluation, prescriptive exercise, and cardiovascular risk factor modification (Tse et al., 2011). The purpose of this project is to determine the feasibility of enrolling breast cancer patients treated with anthracycline +/- trastuzumab who also have a decreased left ventricular ejection fraction in CR to reduce future CVD. A systematic literature search was conducted to determine existing clinical guidelines in cardio-oncology rehabilitation for patients undergoing anthracycline +/- trastuzumab therapy. Select guidelines were adapted using RNAO’s (2012) Toolkit: Implementation of Best Practice Guidelines. The CR program, supported by the European Society of Cardiology guidelines on cardio-oncology (Lyon et al., 2022), includes usual standard of care and tailored as needed to this population. To evaluate the feasibility of this project, CR program components and patient outcomes will be monitored. Existing clinical guidelines were systematically adapted and implemented using the RNAO Toolkit to tailor a CR referral process and program for cardio-oncology patients at a tertiary care institution. This project is the first step to determining if CR has the potential to reduce future CVD risk in this growing patient population.

Speakers / Panelists

    {$photo-alt}

    Freya Kelly
    RN